Finance

Beta
Lists
2AB:FRA
Barinthus Biotherapeutics PLC - ADR
€0.58
0.00%
(0.00) 1D
Jun 5, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 2AB...
Open
€0.58
High
€0.58
Low
€0.58
Mkt. cap
26.67M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.54
52-wk low
€0.45
No. of employees
14
Open
€0.58
High
€0.58
Low
€0.58
Mkt. cap
26.67M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.54
52-wk low
€0.45
No. of employees
14
News stories
From sources across the web
Profile
Barinthus Biotherapeutics plc is a biotechnology company developing immunotherapies for infectious diseases, cancer and autoimmune diseases such as hepatitis B, HPV and prostate cancer. Formerly known as Vaccitech plc, in November 2023 the company announced that it had renamed itself to Barinthus Biotherapeutics plc. As of 2024, the company employs more than 100 people. Wikipedia
About Barinthus Biotherapeutics PLC - ADR
CEO-
Employees14
Founded2016
Headquarters-
SectorBiotechnology
Websitebarinthusbio.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-1.00K
-308.00K
374.00K
271.00K
Cost of revenue
-1.00K
-308.00K
374.00K
271.00K
Research and development expenses
6.61M
5.46M
3.44M
3.17M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
15.38M
5.15M
1.50M
2.38M
Operating expense
21.98M
10.53M
4.51M
5.50M
Total operating expenses
21.98M
10.23M
4.88M
5.78M
Operating income
-21.98M
-10.23M
-4.88M
-5.78M
Other non operating income
320.00K
-275.00K
-104.00K
39.00K
EBT including unusual items
-21.15M
-14.64M
-11.16M
-5.55M
EBT excluding unusual items
-21.15M
-10.04M
-4.59M
-5.40M
Income tax expense
-25.00K
-71.00K
-57.00K
-16.00K
Effective tax rate
0.12%
0.48%
0.51%
0.29%
Other operating expenses
-13.00K
-72.00K
-434.00K
-46.00K
Net income
-21.12M
-14.57M
-11.09M
-5.53M
Net profit margin
-
-
-
-
Earnings per share
-0.52
-0.24
-0.27
-0.14
Interest and investment income
523.00K
472.00K
406.00K
350.00K
Interest expense
-12.00K
-13.00K
-13.00K
-13.00K
Net interest expenses
511.00K
459.00K
393.00K
337.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-20.78M
-10.12M
-4.57M
-5.52M
Gain or loss from assets sale
-281.00K
-68.00K
104.00K
-38.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer